Display options
Cite
Yata T, Lee KY, Dharakul T, et al. Hybrid Nanomaterial Complexes for Advanced Phage-guided Gene Delivery. Mol Ther Nucleic Acids. 2014;3:e185doi: 10.1038/mtna.2014.37.
Yata, T., Lee, K. Y., Dharakul, T., Songsivilai, S., Bismarck, A., Mintz, P. J., & Hajitou, A. (2014). Hybrid Nanomaterial Complexes for Advanced Phage-guided Gene Delivery. Molecular therapy. Nucleic acids, 3e185. https://doi.org/10.1038/mtna.2014.37
Yata, Teerapong, et al. "Hybrid Nanomaterial Complexes for Advanced Phage-guided Gene Delivery." Molecular therapy. Nucleic acids vol. 3 (2014): e185. doi: https://doi.org/10.1038/mtna.2014.37
Yata T, Lee KY, Dharakul T, Songsivilai S, Bismarck A, Mintz PJ, Hajitou A. Hybrid Nanomaterial Complexes for Advanced Phage-guided Gene Delivery. Mol Ther Nucleic Acids. 2014 Aug 12;3:e185. doi: 10.1038/mtna.2014.37. PMID: 25118171; PMCID: PMC4221597.
Copy Download .nbib Format: NLM
Share it on

Mol Ther Nucleic Acids. 2014 Aug 12;3:e185. doi: 10.1038/mtna.2014.37.

Hybrid Nanomaterial Complexes for Advanced Phage-guided Gene Delivery.

Molecular therapy. Nucleic acids

Teerapong Yata, Koon-Yang Lee, Tararaj Dharakul, Sirirurg Songsivilai, Alexander Bismarck, Paul J Mintz, Amin Hajitou

Affiliations

  1. Phage Therapy Group, Department of Medicine, Imperial College London, London, UK.
  2. Polymers and Composites Engineering (PaCE) Group, Department of Chemical Engineering, Imperial College London, London, UK.
  3. National Nanotechnology Center, National Science and Technology Development Agency, Khlong Luang Pathumthani, Thailand.
  4. Department of Surgery and Cancer, Imperial College London, London, UK.

PMID: 25118171 PMCID: PMC4221597 DOI: 10.1038/mtna.2014.37

Abstract

Developing nanomaterials that are effective, safe, and selective for gene transfer applications is challenging. Bacteriophages (phage), viruses that infect bacteria only, have shown promise for targeted gene transfer applications. Unfortunately, limited progress has been achieved in improving their potential to overcome mammalian cellular barriers. We hypothesized that chemical modification of the bacteriophage capsid could be applied to improve targeted gene delivery by phage vectors into mammalian cells. Here, we introduce a novel hybrid system consisting of two classes of nanomaterial systems, cationic polymers and M13 bacteriophage virus particles genetically engineered to display a tumor-targeting ligand and carry a transgene cassette. We demonstrate that the phage complex with cationic polymers generates positively charged phage and large aggregates that show enhanced cell surface attachment, buffering capacity, and improved transgene expression while retaining cell type specificity. Moreover, phage/polymer complexes carrying a therapeutic gene achieve greater cancer cell killing than phage alone. This new class of hybrid nanomaterial platform can advance targeted gene delivery applications by bacteriophage.

References

  1. Virology. 2009 Apr 25;387(1):89-97 - PubMed
  2. Gastroenterology. 2006 Nov;131(5):1370 - PubMed
  3. Biochem Biophys Res Commun. 1996 May 24;222(3):694-9 - PubMed
  4. Nat Protoc. 2007;2(3):523-31 - PubMed
  5. J Gene Med. 2005 May;7(5):657-63 - PubMed
  6. Int J Radiat Biol. 2007 Nov-Dec;83(11-12):849-71 - PubMed
  7. Cell. 2006 Apr 21;125(2):385-98 - PubMed
  8. Mol Oncol. 2013 Feb;7(1):55-66 - PubMed
  9. Virology. 2001 Mar 30;282(1):102-12 - PubMed
  10. J Mol Med (Berl). 2004 Jul;82(7):467-76 - PubMed
  11. Biomaterials. 2009 Oct;30(29):5767-74 - PubMed
  12. J Biol Chem. 1994 Apr 29;269(17):12468-74 - PubMed
  13. Bioorg Med Chem Lett. 2014 Apr 1;24(7):1771-5 - PubMed
  14. Biotechnol Appl Biochem. 2008 Nov;51(Pt 3):141-51 - PubMed
  15. Eur Biophys J. 2010 Mar;39(4):541-50 - PubMed
  16. Mol Cell Biochem. 2005 Aug;276(1-2):113-9 - PubMed
  17. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):7934-8 - PubMed
  18. J Control Release. 1998 Apr 30;53(1-3):301-10 - PubMed
  19. AAPS J. 2006;8(4):E731-42 - PubMed
  20. J Pharmacol Exp Ther. 1998 Oct;287(1):408-15 - PubMed
  21. Curr Opin Mol Ther. 2001 Apr;3(2):159-69 - PubMed
  22. J Control Release. 2001 May 14;72(1-3):171-8 - PubMed
  23. Lett Appl Microbiol. 2010 Oct;51(4):363-9 - PubMed
  24. Curr Protoc Mol Biol. 2001 May;Chapter 1:Unit1.14 - PubMed
  25. Hum Gene Ther. 1998 Nov 1;9(16):2393-9 - PubMed
  26. Mol Cancer Ther. 2009 Aug;8(8):2383-91 - PubMed
  27. J Control Release. 2009 Jul 20;137(2):130-5 - PubMed
  28. J Biomol Screen. 2004 Jun;9(4):273-85 - PubMed
  29. PLoS One. 2010 Dec 28;5(12):e15576 - PubMed
  30. Exp Cell Res. 1992 Apr;199(2):323-9 - PubMed
  31. Nat Biotechnol. 2000 Aug;18(8):893-5 - PubMed
  32. Biochim Biophys Acta. 1999 Jan 11;1448(3):450-62 - PubMed
  33. BMC Biol. 2012 Mar 22;10:29 - PubMed
  34. Nat Rev Genet. 2007 Aug;8(8):573-87 - PubMed
  35. Mol Cancer Ther. 2012 Dec;11(12):2566-77 - PubMed
  36. Biochem J. 2004 Jan 1;377(Pt 1):159-69 - PubMed
  37. J Biol Chem. 2012 Oct 19;287(43):35849-59 - PubMed
  38. BMB Rep. 2010 Dec;43(12):781-8 - PubMed
  39. Annu Rev Biochem. 2005;74:711-38 - PubMed
  40. Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4471-6 - PubMed
  41. Cancer Res. 1991 Jun 1;51(11):3062-6 - PubMed
  42. Biotechnol Prog. 2007 Mar-Apr;23(2):480-7 - PubMed
  43. Int J Nanomedicine. 2012;7:1575-86 - PubMed
  44. J Biol Chem. 1997 Sep 26;272(39):24198-202 - PubMed
  45. Nano Today. 2010 Dec 1;5(6):524-539 - PubMed
  46. Science. 2002 Jun 28;296(5577):2404-7 - PubMed
  47. Cancer. 2009 Jan 1;115(1):128-39 - PubMed
  48. Nat Mater. 2009 Jul;8(7):543-57 - PubMed
  49. Small. 2008 Sep;4(9):1406-15 - PubMed

Publication Types

Grant support